Table of Contents
Senate Bill S.4031, the Innovative Therapies Centers of Excellence Act, would authorize the Department of Veterans Affairs to establish specialized centers studying psilocybin, MDMA, ibogaine, ketamine, and 5-MeO-DMT for conditions including PTSD and depression. The bill has been introduced but has not yet passed into law.
- A federal framework, not access: S.4031 does not authorize patient access to psychedelics or change drug scheduling. It would give the VA authority to run structured, coordinated research programs.
- Five compounds named explicitly: The bill identifies psilocybin, MDMA, ibogaine, ketamine, and 5-MeO-DMT as the substances to be studied across conditions including PTSD, traumatic brain injury, depression, substance use disorders, and chronic pain.
- The VA as a research platform: Advocates argue the VA’s scale, integrated patient-tracking systems, and high rates of treatment-resistant conditions make it a uniquely credible site for generating the large, consistent datasets federal regulators require.
- Early legislative stage: As of the source publication, S.4031 had been referred to the Senate Committee on Veterans’ Affairs with no hearing or markup scheduled. Its passage is not guaranteed.
What the Research Examined
S.4031, the Innovative Therapies Centers of Excellence Act, was introduced in the United States Senate on March 9, 2026, by Senators Ruben Gallego, Tim Sheehy, and David McCormick. It would direct the Department of Veterans Affairs to establish specialized research and treatment centers focused on psychedelic and related compounds, with authorized annual funding of $30 million. The bill explicitly names psilocybin, MDMA, ibogaine, ketamine, and 5-MeO-DMT as the compounds under study, targeting PTSD, traumatic brain injury, depression, substance use disorders, and chronic pain.
The bill’s design reflects a specific strategic logic: the VA is one of the few institutions in the country that tracks patients longitudinally, applies consistent standards across dozens of sites, and serves a population with documented high rates of treatment-resistant conditions. Supporters, including Melissa Lavasani of the Psychedelic Medicine Coalition, argue that this combination makes the VA capable of producing the kind of large-scale, reproducible outcome data that federal regulators and insurers would require before any broader standard-of-care change. The House companion measure, H.R. 2623, was introduced by Representatives Lou Correa and Jack Bergman, co-chairs of the Psychedelics Advancing Therapies Caucus, giving the legislation a bicameral foundation. For readers following the broader arc of federal psychedelic policy and decriminalization, this bill represents a meaningful, if cautious, institutional step.
As of the Psychedelics Today report published March 17, 2026, the bill had been referred to the Senate Committee on Veterans’ Affairs, and no hearing or markup had been scheduled. The legislation does not address drug scheduling, DEA oversight, reimbursement models, workforce development outside federal institutions, or access beyond the VA. Authorization is the beginning; appropriations and implementation would determine whether any centers actually open.
What the Findings Show
- Authorized funding.The bill, as confirmed by its introduced text, authorizes $30 million annually for the VA centers of excellence.
- Compounds named.Five substances are explicitly listed: psilocybin, MDMA, ibogaine, ketamine, and 5-MeO-DMT.
- Conditions targeted.The bill covers PTSD, traumatic brain injury, depression, substance use disorders, and chronic pain as the primary research targets.
- Legislative status.Referred to the Senate Committee on Veterans’ Affairs on March 9, 2026; no hearing or markup scheduled as of the source publication date.
The core argument behind the bill’s structure is that the field’s persistent problem has not been a lack of early evidence or interest, but the absence of large, consistent datasets generated from real patients inside functioning clinical institutions. S.4031 is designed to produce exactly that, at a scale and under a standardization that smaller academic or nonprofit trials have not been able to achieve. Whether it passes, and whether funding follows authorization, remain open questions.
What would Senate Bill S.4031 actually do for psychedelic research?
If passed, S.4031 would authorize the VA to build specialized research centers studying psilocybin, MDMA, ibogaine, ketamine, and 5-MeO-DMT for veterans with PTSD and related conditions, with $30 million in annual funding. It would not expand patient access or change drug scheduling.
What This Is, and What It Is Not
This is This recap covers a legislative proposal, S.4031, as reported by Psychedelics Today, an industry news outlet. It is not a peer-reviewed clinical study.
This is not This is not evidence that psychedelic therapies have been proven effective or safe for veterans, and it is not medical advice. The bill has not passed; no VA centers exist yet, and no established protocol or approved treatment pathway has been created by this legislation.
Our Take
Within this community, psilocybin and its companions are understood as sacraments that carry genuine healing potential. Watching that potential move into a federal legislative framework carries a quiet weight: the language shifts to protocols, datasets, and regulatory timelines, which can feel distant from the intimacy of actual healing. And yet the veterans this bill is designed to serve are among those carrying some of the heaviest burdens in our society. If rigorous, coordinated research inside an institution as large as the VA can eventually open a responsible door for them, that outcome is worth honoring, even if the path is slower and more institutional than any of us would choose. We hold the science and the sacred in the same open hands.
If this legislation speaks to something you are already carrying, whether curiosity about how policy shapes access, or a personal connection to the veteran community, we invite you to stay close to this conversation as it unfolds. The Mycelium Report will track S.4031’s progress through committee. In the meantime, the Grounding and Integration stations of the Golden Path are always open to those sitting with big questions about healing, access, and what it means to wait for a door to open. You are welcome here.
Frequently Asked Questions
What is Senate Bill S.4031?
S.4031, the Innovative Therapies Centers of Excellence Act, is a bipartisan U.S. Senate bill introduced in March 2026. It would authorize the Department of Veterans Affairs to establish research centers studying psilocybin, MDMA, ibogaine, ketamine, and 5-MeO-DMT for PTSD and related conditions.
Does S.4031 make psychedelics legal for veterans?
No. The bill does not change drug scheduling, DEA oversight, or patient access. It would only give the VA authority to run structured research programs. Psychedelics would remain outside standard care unless future regulatory action follows from the evidence produced.
Why is the VA being used for psychedelic research?
The VA operates as a single integrated system, tracks patients over long periods, applies consistent standards across sites, and serves a population with high rates of treatment-resistant PTSD and depression. Supporters argue this makes it uniquely capable of generating credible, large-scale outcome data.
How much funding does S.4031 authorize?
The bill authorizes $30 million annually for the VA centers of excellence. Authorization does not guarantee appropriation; Congress would still need to allocate the actual funds in a separate process.
What is the current status of S.4031?
As of March 2026, S.4031 had been referred to the Senate Committee on Veterans’ Affairs. No hearing or markup had been scheduled. A companion House bill, H.R. 2623, was introduced separately by members of the PATH Caucus.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
